Dec 12 (Reuters) - Keros Therapeutics ( KROS ) said on
Thursday that it has voluntarily halted dosing of its 3.0
milligram (mg) and 4.5 mg doses of its high blood pressure
treatment in a mid-stage study based on a safety review.
(Reporting by Sneha S K; Editing by Abinaya Vijayaraghavan)